ADRB2 and obesity disorder: Importantly, PHDi treatment of human abdominal subcutaneous white adipocytes from individuals with obesity increased ADRB2 mRNA levels (Fig. 7E), a pathway recently shown to be the main target for pharmacological activation of human brown adipocytes41.